{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267745","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.231342+00:00","generated_at":"2026-06-09T02:26:14.259788+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated","bullets":["Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.","Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.","Cowen will receive up to 3.0% commission on gross proceeds from sales.","ATM offering made under existing shelf registration statement (File No. 333-269899)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267745","json":"https://secwatch.observer/filing/0001193125-23-267745.json","markdown":"https://secwatch.observer/filing/0001193125-23-267745.md","text":"https://secwatch.observer/filing/0001193125-23-267745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/d282676d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:26:14.259788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d91391071d7ccb99a082b52e6293af961e1be29","claim":"Apellis Pharmaceuticals, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC valued at up to $300.0 million (effective 2023-10-31).","evidence_excerpt":"In connection with the entry into the Agreement, on October 31, 2023, the Company terminated its prior Open Market Sale Agreement SM , dated as of January 20, 2022 (the “Prior Agreement”), by and between the Company and Jefferies LLC (“Jefferies”), in accordance with its terms.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"up to $300.0 million"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"},{"claim_id":"f68f181340603dcf6d4819c182705814c264f60c","claim":"Apellis Pharmaceuticals, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-01).","evidence_excerpt":"On November 1, 2023, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Agreement”) with Cowen and Company, LLC, as agent (“Cowen”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Shares”), from time to time through Cowen (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cowen and Company, LLC"},{"label":"Value","value":"up to $300.0 million"},{"label":"Effective","value":"2023-11-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}